Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function

International Heart Journal

Volumn 50, Issue 1, 2009, Pages 73-83

  Ono, Yoshifumi ^b,c   Nakaya, Yutaka ^a   Bando, Shigenobu ^b   Soeki, Takeshi ^b   Ito, Susumu ^b   Sata, Masataka ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Kagawa Prefectural Shirotori Hospital   (Japan)

^c NONE   (Japan)

Author keywords

ADMA; Essential hypertension; PPAR ; Telmisartan; Vascular endothelial function

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; HEMOGLOBIN A1C; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN;

AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; MORNING DOSAGE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PULSE WAVE;

ADMINISTRATION, ORAL; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ARGININE; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; MALE; NITRIC OXIDE SYNTHASE TYPE III; PPAR GAMMA; TREATMENT OUTCOME;

EID: 61749087602     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.50.73     Document Type: Article

References (35)

1. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-8.
2. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
3. Cooke JP, Dzau VJ. Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation 1997; 96: 379-82. (Review)
4. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20: S60-2.
5. Delles C, Schneider MP, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N (G), N (G) - dimethylarginine in human essential hypertension. Am J Hypertens 2002; 15: 590-3.
6. Ito A, Egashira K, N arishige T, Muramatsu K, Takeshita A. Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn Circ J 2001; 65: 775-8.
7. Benson SC, Pershadsingh HA, Ho CI, et al. ldenitication of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
8. Picard E Auwerx J. PPAR (gamma) and glucose homeostasis. Annu Rev Nutr 2002; 22: 167-97. (Review)
9. Walczak R, Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J Lipid Res 2002; 43: 177-86. (Review)
10. Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN. Peroxisome prolifemtor-activated receptors: vascular and cardiac effects in hypertension. Hypertension 2003; 42: 664-8.
11. Kim JY, Tillison K, Lee JH, Rearick DA, Smas CM. The adipose tissue triglyceride lipase ATGL/PNPLA2 is downregulated by insulin and TNF-alpha in 3T3-L1 adipocytes and is a target for transactivation by PPARgamma. Am J Physiol Endocrinol Metab 2006; 291: E115-27.
12. Dolezalová R, Haluzik MM, Bosanská L, et al. Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus. Physiol Res 2007; 56: 741-8.
13. Law RE, Goetze S, Xi XP, et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000; 101: 1311-8.
14. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptorgamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
15. Wakino S, Law RE, Hsueh WA. Vascular protective effects by activation of nuclear recept PPAR-gamma. J Diabetes complications 2002; 16: 46-9. (Review)
16. Hsueh WA, Law R. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am J Cardiol 2003; 92: 3J-9. (Review)
17. Hsueh WA, Law RE. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Bio 2001; 21: 1891-5. (Review)
18. Diep QN, EI Mabrouk M, Cohn JS, et al. Structure. endothelial function. cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptorgamma. Circulation 2002; 105: 2296-302.
19. Perticone E Sciacqua A, Maio R, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005; 46: 518-23.
20. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-95.
21. Valkonen VP, Päivä H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-8.
22. Fard A, Tuck CH, Donis JA, et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2000; 20: 2039-44.
23. Päivä H, Laakso J, Lehtimäki T, Isomustajärvi M, Ruokonen I, Laaksonen R. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol 2003; 41: 219-22.
24. Napoli C, Sica V, de Nigris E et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148: e5.
25. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032-7. (Review)
26. Lehmann ED. Clinical value of aortic pulse-wave velocity measurement, Lancet 1999; 354: 528-9.
27. O'Sullivan C, Duggan J, Lyons S, Thomton J, Lee M, O'Brien E. Hypertensive target-organ damage in the very elderly. Hypertension 2003; 42: 130-5.
28. Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility. and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25: 359-64.
29. Kobayashi K, Akishita M, Yu W, Hashimoto M, Olmi M, Toba K. Interrelationship between non-invasive measurements of atherosclerosis: flow-mediated dilation of brachial artery, carotid intima-media thickness and pulse wave velocity. Atherosclerosis 2004; 173: 13-8.
30. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999; 100: 354-60.
31. Waki H, Yamauchi T, Kamon J, e al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003; 278: 40352-63.
32. Rizzoni D, Muiesan ML, Porteri E, et al' Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J Hypertens 1997; 15: 197-204.
33. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of artetial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-9.
34. Amar J, Ruidavets JB, Chamontin B, Drouet L, Ferrières J. Arterial stiffness and cardiovascular risk factors in a population-based study. J Hypertens 2001; 19: 381-7.
35. Takiuchi S, Fujii H, Kamide K, et al. Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. Am J Hypertens 2004; 17: 802-8.